Literature DB >> 12610236

Rehab rounds: use of the Americans with Disabilities Act by young adults with schizophrenia.

Deborah Gioia1, John S Brekke.   

Abstract

Introduction by the column editors: People with mental illness have consistently identified employment as a strong unmet need, yet only one in five people with schizophrenia has been able to work in full-time competitive employment and less than 50 percent work at all, despite the advent of evidence-based services, such as supported employment (1,2). However, there are compelling developmental, clinical, and economic reasons for people with mental illnesses to pursue competitive employment as they attempt to normalize and reconstruct their lives (3). Even with a mainstreaming ideology that encourages everyone who wants work to seek it, the real challenges are to organize supportive employment services, match people to jobs, and sustain clients in a continuum of work rehabilitation (4). Several Rehab Rounds columns have focused on programs aimed at enhancing the work functioning of people with serious mental disorders by using supported employment (5), increasing work readiness (6), and teaching fundamental workplace skills (7). In this month's column, Deborah Gioia and John S. Brekke describe the impact of the Americans With Disabilities Act on the work experience of young adults with schizophrenia.

Entities:  

Mesh:

Year:  2003        PMID: 12610236     DOI: 10.1176/appi.ps.54.3.302

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  2 in total

Review 1.  Career development in schizophrenia: a heuristic framework.

Authors:  Deborah Gioia
Journal:  Community Ment Health J       Date:  2005-06

2.  Enhancing return to work or school after a first episode of schizophrenia: the UCLA RCT of Individual Placement and Support and Workplace Fundamentals Module training.

Authors:  Keith H Nuechterlein; Kenneth L Subotnik; Joseph Ventura; Luana R Turner; Michael J Gitlin; Denise Gretchen-Doorly; Deborah R Becker; Robert E Drake; Charles J Wallace; Robert P Liberman
Journal:  Psychol Med       Date:  2019-01-04       Impact factor: 7.723

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.